Petefészekrák: vizsgálatok itt: Spanyolország
88 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Barcelona, Madrid, Málaga, Vigo
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Barcelona, Palma de Mallorca, Patraix
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 1. fázisTaking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Where
- Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- A Coruña, Badalona, Barcelona, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Pamplona, Sabadell, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - 1/2. fázisTaking peopleFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Where
- Barcelona, Girona, Huelva, Logrono, Madrid, Majadahonda, Pamplona, Pozuelo de Alarcón, Toledo
- Életkor
- 18 év and over
- People
- 334 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01 - 3. fázisTaking peopleA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Barcelona, Córdoba, Donostia, Madrid, Murcia, Santiago De Compostela, Valencia
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00 - 3. fázisTaking peoplePhase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
- Where
- Barcelona, Bilbao, Jaén, Madrid, Málaga, Vigo
- Életkor
- 18 év and over
- People
- 197 worldwide
- Run by
- K-Group Beta Inc.
See details and how to join2025-524641-27-00 · EU 2025-524641-27-00 - 2. fázisTaking peopleA Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Where
- Barcelona, Madrid, Majadahonda, Murcia, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 310 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825 · EU 2022-502983-19-00 - 1/2. fázisTaking peopleA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 605 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00 - 2. fázisTaking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- A Coruña, Barcelona, Córdoba, Donostia, Girona, L'Hospitalet de Llobregat, Madrid, Murcia, Palma, Pamplona, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - 1/2. fázisTaking peopleA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 248 worldwide
- Run by
- Terremoto Biosciences Inc.
See details and how to joinNCT07109726 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Badalona, Barcelona, Jaén, Madrid, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid, Málaga, Seville, Valencia
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 2. fázisTaking peopleA Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Where
- Alicante, Granada, Lugo, Madrid, Manresa, Reus, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 640 worldwide
- Run by
- North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000 · EU 2022-502559-69-01 - 1/2. fázisTaking peopleA Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Where
- A Coruña, Badalona, Barcelona, Córdoba, Elche, El Palmar, Girona, Lleida, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Rioja, Sabadell, Santander, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 542 worldwide
- Run by
- Artios Pharma Ltd
See details and how to joinNCT04657068 - 1. fázisTaking peopleAnti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00 - 3. fázisTaking peopleTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- A Coruña, Barakaldo, Barcelona, Granollers, Madrid
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00 - 1/2. fázisTaking peopleA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Where
- Barcelona, Logroño, Madrid, Pozuelo de Alarcón
- Életkor
- 18 év and over
- People
- 245 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00 - 3. fázisTaking peopleStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Badalona, Barcelona, Madrid, Málaga, Oviedo, Palma, Pamplona, Sabadell, Sevilla, Valencia, Vitoria
- Életkor
- 18 év and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00